COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01189084
Recruitment Status : Completed
First Posted : August 26, 2010
Last Update Posted : July 13, 2011
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital
Information provided by:
United Biomedical

Brief Summary:
The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed with mild or moderate Alzheimer's disease (AD) who previously received UB 311-treatment. Amyloid beta was selected as the target antigen based on supporting evidence of the hypothesis that places the accumulation of amyloid beta at the initiating step of AD.

Condition or disease Intervention/treatment
Alzheimer's Disease Biological: Observational

Layout table for study information
Study Type : Observational
Actual Enrollment : 14 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Study to the Patients With Alzheimer's Disease Who Previously Received UB311-Treatment in the V118-AD Trial
Study Start Date : April 2010
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Observational immunotherapy follow-up Biological: Observational
Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).

Primary Outcome Measures :
  1. Immunogenicity [ Time Frame: 24 weeks ]
    Long-term followup to week 48

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 24 weeks ]
    Long-term followup to week 48

Biospecimen Retention:   Samples Without DNA
Periodic blood samples collected for serum and measurement of anti-Amyloid-beta antibody levels.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Enrolled subjects who received UB 311-treatment in the initial UBI Protocol V118 (Protocol V118-AD) Phase I trial are eligible for continued follow-up to week 48

Inclusion Criteria:

  • Individuals with mild to moderate Alzheimer's disease who received three (3) injections of UB 311 in the initial Phase I V118-AD trial

Exclusion Criteria:

  • Individuals with Alzheimer's disease who are currently on prohibited medications, have severe or uncontrolled systemic disease, or are unable or unwilling to comply with study protocol requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01189084

Layout table for location information
National Taiwan University Hospital (NTUH)
Taipei, Taiwan, 10002
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Sponsors and Collaborators
United Biomedical
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital
Layout table for investigator information
Principal Investigator: Pei-Ning Wang, M.D. Taipei Veterans General Hospital (TVGH)
Principal Investigator: Ming-Jang Chiu, M.D. National Taiwan University Hospital (NTUH)
Additional Information:
Layout table for additonal information
Responsible Party: Pei-Ning Wang, M.D., Principal Investigator, Taipei Veterans General Hospital (TVGH) Identifier: NCT01189084    
Other Study ID Numbers: UBI Protocol V118-obs
First Posted: August 26, 2010    Key Record Dates
Last Update Posted: July 13, 2011
Last Verified: July 2011
Keywords provided by United Biomedical:
Alzheimer's disease
amyloid beta
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders